Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension

PHASE3CompletedINTERVENTIONAL

Enrollment

448

Participants

Timeline

Start Date

March 28, 2018

Primary Completion Date

October 31, 2018

Study Completion Date

December 18, 2018

Conditions

Cataract

Interventions

DRUG

Nepafenac 0.3% Oph Susp

Nepafenac 0.3% Ophthalmic suspension (experimental product)

DRUG

Placebos

Placebo

DRUG

Nepafenac 0.3% Oph Susp (reference)

Nepafenac 0.3% Ophthalmic suspension (Innovator)

Trial Locations (1)

Key-Whitman Eye Center, Dallas